Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study

Journal of Gastroenterology and Hepatology (Australia)

Volumn 30, Issue 12, 2015, Pages 1705-1712

  Jung, Yoon Suk ^a   Park, Dong Il ^a   Kim, Young Ho ^b   Lee, Ji Hyun ^c   Seo, Pyoung Ju ^c   Cheon, Jae Hee ^d   Kang, Hyoun Woo ^f   Kim, Ji Won ^e  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Seoul Song Do Colorectal Hospital   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

^e Seoul National University Boramae Hospital   (South Korea)

^f Dongguk University Ilsan Hospital   (South Korea)

Author keywords

Biosimilar; Crohn's disease; Infliximab; Ulcerative colitis

Indexed keywords

CT-P13; INFLIXIMAB; MONOCLONAL ANTIBODY;

ADULT; FEMALE; HUMAN; INFLAMMATORY BOWEL DISEASES; MALE; MULTICENTER STUDY (TOPIC); REMISSION; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; INFLIXIMAB; MALE; MULTICENTER STUDIES AS TOPIC; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84940081554     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12997     Document Type: Article

References (34)

1. Hanauer SB, Feagan BG, Lichtenstein GR etal. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-1549.
2. Sands BE, Anderson FH, Bernstein CN etal. Infliximab maintenance therapy for fistulizing Crohn's disease. N. Engl. J. Med. 2004; 350: 876-885.
3. Rutgeerts P, Sandborn WJ, Feagan BG etal. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 2005; 353: 2462-2476.
4. Hanauer SB, Sandborn WJ, Rutgeerts P etal. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323-333, quiz 591.
5. Sandborn WJ, van Assche G, Reinisch W etal. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142: 257-265, e1-3.
6. Schnitzler F, Fidder H, Ferrante M etal. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009; 58: 492-500.
7. Kotze PG, Saad-Hossne R. Biological therapy for the prevention and treatment of postoperative endoscopic recurrence in Crohn's disease: time for acceptance? Intest. Res. 2013; 11: 256-260.
8. Jeong SY, Moon JS, Park KJ, Kim YS. Successful treatment of postoperative fistula with infliximab in a patient with Crohn's disease. Intest. Res. 2014; 12: 74-77.
9. Fiorino G, Danese S. The biosimilar road in inflammatory bowel disease: the right way? Best Pract. Res. Clin. Gastroenterol. 2014; 28: 465-471.
10. Crommelin D, Bermejo T, Bissig M etal. Biosimilars, generic versions of the first generation of therapeutic proteins: do they exist? Contrib. Nephrol. 2005; 149: 287-294.
11. Rinaudo-Gaujous M, Paul S, Tedesco ED, Genin C, Roblin X, Peyrin-Biroulet L. Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases. Aliment. Pharmacol. Ther. 2013; 38: 914-924.
12. Kang YS, Moon HH, Lee SE, Lim YJ, Kang HW. Clinical experience of the use of CT-P13, a biosimilar to infliximab in patients with inflammatory bowel disease: a case series. Dig. Dis. Sci. 2015; 60: 951-956.
13. Hlavaty T. Letkovsky J. Biosimilars in the therapy of inflammatory bowel diseases. Eur. J. Gastroenterol. Hepatol. 2014; 26: 581-587.
14. Yoo DH, Hrycaj P, Miranda P etal. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann. Rheum. Dis. 2013; 72: 1613-1620.
15. Park W, Hrycaj P, Jeka S etal. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann. Rheum. Dis. 2013; 72: 1605-1612.
16. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand. J. Gastroenterol. Suppl. 1989; 170: 2-6, discussion 16-19.
17. Silverberg MS, Satsangi J, Ahmad T etal. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can. J. Gastroenterol. 2005; 19 (Suppl. A): 5a-36a.
18. Stange EF, Travis SP, Vermeire S etal. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut 2006; 55 (Suppl. 1): i1-15.
19. Lee KM, Jeen YT, Cho JY etal. Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: a Korean multicenter retrospective study. J. Gastroenterol. Hepatol. 2013; 28: 1829-1833.
20. Ardizzone S, Colombo E, Maconi G etal. Infliximab in treatment of Crohn's disease: the Milan experience. Dig. Liver Dis. 2002; 34: 411-418.
21. Targan SR, Hanauer SB, van Deventer SJ etal. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's disease cA2 study group. N. Engl. J. Med. 1997; 337: 1029-1035.
22. Present DH, Rutgeerts P, Targan S etal. Infliximab for the treatment of fistulas in patients with Crohn's disease. N. Engl. J. Med. 1999; 340: 1398-1405.
23. Orlando A, Colombo E, Kohn A etal. Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study. Dig. Liver Dis. 2005; 37: 577-583.
24. Kim YJ, Kim JW, Lee CK etal. Clinical outcome of treatment with infliximab in Crohn's disease: a single-center experience. Korean J. Gastroenterol. 2013; 61: 270-278.
25. Choi CH, Song ID, Kim YH etal. Efficacy, safety, and predictors of response to infliximab therapy in Korean patients with Crohn's disease: a nationwide, multicenter study. Hepatogastroenterology 2015.
26. Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010; 59: 49-54.
27. Jurgens M, Laubender RP, Hartl F etal. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. Am. J. Gastroenterol. 2010; 105: 1811-1819.
28. Ferrante M, Vermeire S, Katsanos KH etal. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm. Bowel Dis. 2007; 13: 123-128.
29. Ferrante M, Vermeire S, Fidder H etal. Long-term outcome after infliximab for refractory ulcerative colitis. J. Crohns Colitis 2008; 2: 219-225.
30. Su C, Salzberg BA, Lewis JD etal. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am. J. Gastroenterol. 2002; 97: 2577-2584.
31. Oussalah A, Evesque L, Laharie D etal. A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization. Am. J. Gastroenterol. 2010; 105: 2617-2625.
32. Gonzalez-Lama Y, Fernandez-Blanco I, Lopez-SanRoman A etal. Open-label infliximab therapy in ulcerative colitis: a multicenter survey of results and predictors of response. Hepatogastroenterology 2008; 55: 1609-1614.
33. Seo HI, Park DI, Kim TO etal. The effect of infliximab on patients with ulcerative colitis in Korea. Intest. Res. 2014; 12: 214-220.
34. Schellekens H. Immunologic mechanisms of EPO-associated pure red cell aplasia. Best Pract. Res. Clin. Haematol. 2005; 18: 473-480.